



David A Cooper

Contact

David A Cooper

Publications (3)

Hurst J, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher A, Phillips R, Fisher M, Brown H, Hoffmann M, Pace M, Williams J, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch K, Robinson N, Frater J. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. *Nat Commun* 2015; 6:8495.

Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. *J Acquir Immune Defic Syndr* 2013; 62:171-9.

Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial. *J Acquir Immune Defic Syndr* 2012

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch